Sandbox gc

Class I

"1. For patients at risk of developing HF, natriuretic peptide biomarker–based screening followed by team- based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset HF (Level of Evidence: B-R) "

Class III (No Benefit)

"1. Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is not recommended for patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF). (Level of Evidence: C) "

Class III (Harm)

"1. ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor. (Level of Evidence: B-R) "

"2. ARNI should not be administered to patients with a history of angioedema. (Level of Evidence: C-EO) "

Class IIa

"1. Angiotensin II receptor blockers are reasonable to use as alternatives to ACE inhibitors as first-line therapy for patients with mild to moderate heart failure and reduced left ventricular ejection fraction (LVEF), especially for patients already taking ARBs for other indications.(Level of Evidence: A) "

Class IIb

"1. Angiotensin II receptor blockers are reasonable to use as alternatives to ACE inhibitors as first-line therapy for patients with mild to moderate heart failure and reduced left ventricular ejection fraction (LVEF), especially for patients already taking ARBs for other indications.(Level of Evidence: A) "